Primary Efficacy Evaluation of Traditional Chinese Medicine in Treating Older Infertile Women

Sponsor
Chang Gung Memorial Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03973528
Collaborator
(none)
17
1
2
28.8
0.6

Study Details

Study Description

Brief Summary

This study is a preliminary evaluation of the efficacy of traditional Chinese medicine in the treatment of elderly infertile women.

Condition or Disease Intervention/Treatment Phase
  • Drug: traditional Chinese medicine: tonifying kidney Wan
Phase 3

Detailed Description

Research design: initial acceptance of 60 people, 30 in the no intervention group and 30 in the experimental group.

The no intervention group no use Traditional Chinese medicine. The experimental group use Traditional Chinese medicine. Affect natural pregnancy and IVF success factors, the quality of ovarian function plays a very important role. Currently used to predict ovarian follicle inventory indicators, including: age, the total number of small sized ovarian follicles, the first three days of menstrual follicle-stimulating hormone, Anti-Mullerian hormone, inhibin-B.

Research Analysis Chang Gung Memorial Hospital infertility patients using traditional Chinese medicine, more than 40-year-old infertility patients, the most commonly used compound is Zuo Gui Wan. Chinese medicine believes that elderly women with infertility ovulation poor, the main pathogenesis of kidney deficiency. The proportion of domestic infertility patients has increased year by year. Traditional Chinese medicine had become popular and acceptable, but the substantial evidence and treatment consensus of infertility are scanty.

Due to the outbreak of the new crown pneumonia epidemic, which made it difficult to accept the case. Only 17 subjects in the experimental group completed the test. The average age of the subjects was 40.11 ±3.09 years old, and 9 of them were over 40 years old. The AMH before the test was all below 1.2. After three months of treatment with traditional Chinese medicine, 16 subjects had an increase in the number of small sized ovarian follicles. The average total number of small ovarian follicles before the test was 3.06±0.90, and the average increased to 4.53±1.46 after treatment. (P<0.05), which was statistically significant. Eleven subjects showed a decrease in follicle-stimulating hormone on the third day of menstruation after treatment, 9 subjects showed an increase in anti-Mullerian hormone (AMH) value after treatment, and 3 subjects had anti-Mullerian hormone (AMH) values higher than 1.2 after treatment, but they did not reach statistical significance.

Study Design

Study Type:
Interventional
Actual Enrollment :
17 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Preliminary Evaluation of the Efficacy of Traditional Chinese Medicine in Treating Elderly Women With Infertility
Actual Study Start Date :
Jul 8, 2019
Actual Primary Completion Date :
Nov 30, 2021
Actual Study Completion Date :
Nov 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: traditional Chinese medicine

The experimental group use traditional Chinese medicine

Drug: traditional Chinese medicine: tonifying kidney Wan
traditional Chinese medicine : tonifying kidney Wan
Other Names:
  • tonifying kidney Wan I: Zuo Gui Wan
  • tonifying kidney Wan II :Guilu Erxian
  • No Intervention: non- traditional Chinese medicine

    The no intervention group no use traditional Chinese medicine.

    Outcome Measures

    Primary Outcome Measures

    1. serum anti-Mullerian hormone (AMH) index [three months]

      The efficacy of traditional Chinese medicine in the treatment of infertile women was evaluated by examining serum anti-Mullerian hormone (AMH) index

    2. total number of small ovarian follicles by the ultrasound examination (menstrual cramps 3-5 days). [three months]

      The efficacy of traditional Chinese medicine in the treatment of infertile women was evaluated by the total number of small ovarian follicles by the ultrasound examination (menstrual cramps 3-5 days).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    35 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
      1. Women aged 35-45, married, without contraception, after 12 months of normal sexual life, did not take any contraceptive measures, and did not successfully conceive women.
    1. Blood tests for serum anti-Mullerian hormone ( AMH) less than 1.2, female hormones FSH, LH, E2 blood test is normal.

    2. Women who are not planning for IUI or IVF in the next three months. D. Menstrual cycle rules 21-35 days. E. Willing to sign a written consent form.

    Exclusion Criteria:
    1. Women with contraceptive. B. Vegetarians or have been taking Traditional Chinese medicine allergies. C. The following diseases have occurred in the past six months: cancer, high blood pressure, diabetes, heart disease, stroke, myocardial infarction, hyperthyroidism or hypothyroidism, chronic hepatitis, gastric ulcer, stomach bleeding, chronic constipation or diarrhea, major trauma and surgery, severe uterine and pelvic infections.

    2. Because of the need for disease, it is currently necessary to take western medicine for more than three months.

    3. Women with abnormal liver function (GOT, GPT greater than 2 times the upper limit of normal).

    4. Women with abnormal renal function (serum creatinine > 1.5 mg/dl). G. Poor compliance with medication. H. In the past month, take a Traditional Chinese medicine to treat infertility. I. Take DHEA for the past month.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chang Gung Memorial Hospital Taoyuan Taiwan 33302

    Sponsors and Collaborators

    • Chang Gung Memorial Hospital

    Investigators

    • Study Chair: Tsang-Tang Hsieh, MD, Chang Gung MH IRB

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Chang Gung Memorial Hospital
    ClinicalTrials.gov Identifier:
    NCT03973528
    Other Study ID Numbers:
    • IRB201702097A3
    • Chang Gung MH
    First Posted:
    Jun 4, 2019
    Last Update Posted:
    Mar 22, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Chang Gung Memorial Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 22, 2022